Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
alternative, antibody, Belgium, blind, combination, concentrated, David, double, ease, easier, fully, healthy, Indemnification, IP, joint, label, listing, middle, percent, POD, produced, Silberman, targeting, turn, venture
Removed:
Avraham, decreased, Gabay, IIb, initiating, recently
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 Employment Agreement, Dated May 23, 2021, Between Oramed LTD. and David Silberman
- 10.2 Representative Form of Indemnification Agreement Between Oramed Pharmaceuticals Inc. and Each of Its Directors and Officers
- 31.1 Certification
- 31.2 Certification
- 32.1 Certification
- 32.2 Certification
- Download Excel data file
- View Excel data file
ORMP similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
In connection with the quarterly report of Oramed Pharmaceuticals Inc., or the Company, on Form 10-Q for the period ended May 31, 2021 as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, David Silberman, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:
(1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: July 14, 2021 | /s/ David Silberman |
David Silberman, Chief Financial Officer |